DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for osteogenesis imperfecta type 3 — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOsteogenesis imperfecta type 3 maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for osteogenesis imperfecta type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
bone morphogenetic protein 1 (BMP1) — BMP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3EDH · 1.25 Å · ligand ACETYL GROUP (ACE). Experimental structure, not a prediction.
What the evidence adds up to
In 1997, the understanding of the biochemical and genetic abnormalities in osteogenesis imperfecta had advanced, and prenatal diagnostic techniques allowed early detection, especially in families with a known molecular defect. Medical and surgical management were said to be improving, but the proper management of problems such as basilar impression still needed to be determined. Progress at a molecular level was described as encouraging.
By 2021, osteogenesis imperfecta was described as a monogenic disorder, caused in most cases by mutations in COL1A1 or COL1A2, with mutations in at least 20 other genes also capable of causing the disease. Clinical manifestation ranges from mild to severe, with possible perinatal lethality. The 2021 review states that therapeutic treatment of osteogenesis imperfecta is symptomatic, and that the search for new treatment strategies aimed at preventing fractures and bone deformity progression continues. The review mentions anabolic therapy and antiresorptive therapy as key words but does not report any trial results for these approaches.
A 2024 case report describes a 39-year-old woman with type I osteogenesis imperfecta who developed a Th12 vertebral compression fracture two days after an elective cesarean section and an L3 vertebral compression fracture three weeks postoperatively. Her lumbar spine Z-score was −1.7. She discontinued breastfeeding and started active vitamin D supplementation. The report notes that little is known about risk factors for fractures or their management during pregnancy or the postpartum period in osteogenesis imperfecta.
What is still missing are completed clinical trials that demonstrate a reduction in fracture risk or improvement in bone density for any specific drug in osteogenesis imperfecta type 3. The 2021 review explicitly calls the current treatment symptomatic. No trial has yet shown that any anabolic or antiresorptive agent prevents fractures or halts deformity progression in this population. Adequate funding for randomised controlled trials, proper patient stratification by genetic subtype, and long-term outcome data remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 1997 · 20 citations
Osteogenesis imperfecta
AbstractIn the past 20 years, tremendous strides have been made in our understanding of the biochemical and genetic abnormalities associated with osteogenesis imperfecta (OI). Prenatal diagnostic techniques have allowed early detection of this disorder, particularly in families in which the actual molecular defect is already known. Although medical and surgical management of patients with OI continue to improve, the proper management of such problems as basilar impression still need to be determined. Progress in the treatment of OI at a molecular level is encouraging.
Osteogenesis imperfecta: classification, clinical features, and treatment
AbstractOsteogenesis imperfecta (OI) is a monogenic disorder characterized by increased bone fragility and several extraskeletal manifestations. In most cases, OI is caused by mutations in one of the two genes encoding alpha chains of type I collagen, COL1A1 or COL1A2. Mutations in at least 20 other genes can also lead to OI. Clinical manifestation of the disease ranges from mild to severe form with possible perinatal lethality. The disease may significantly reduce patient’s quality of life, which requires timely and optimal treatment and a multidisciplinary approach. Currently, the therapeutic treatment of osteogenesis imperfecta is symptomatic, but the search for new treatment strategies aimed at preventing the risk of new fractures and the progression of bone deformity continues. Key words: аnabolic therapy, antiresorptive therapy, сollagen, osteogenesis imperfecta, fracture
Case Reports in Women s Health · 2024 · 0 citations · open access
Postpartum multiple vertebral fractures in a patient with osteogenesis imperfecta type I: A case report and literature review
AbstractA 39-year-old woman with type I osteogenesis imperfecta reported experiencing back pain at 35 weeks of gestation. Two days following an elective cesarean section, the patient developed a Th12 vertebral compression fracture; 3 weeks postoperatively, she sustained an L3 vertebral compression fracture. The patient displayed a lumbar spine Z -score of −1.7; she subsequently discontinued breastfeeding, and treatment with active vitamin D was initiated. Genetic testing confirmed a diagnosis of osteogenesis imperfecta. • Osteogenesis imperfecta increases the risk of pregnancy- and lactation-associated osteoporosis but there are few reports of such cases in the literature. • Little is known about the risk factors for fractures and their management during pregnancy or the postpartum period. • We report the case of a patient with type I osteogenesis imperfecta who developed multiple spinal fractures during the postpartum period. • The patient chose to discontinue breastfeeding, and started on vitamin D supplementation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
